PPARγ stimulation improves cardiovascular risk profile independent from its glucose lowering effects

被引：0
|
作者：
Hohberg, C
Lübben, G
Forst, T
Marx, N
Weber, MM
Löbig, M
Pfützner, A
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A149 / A150
页数：2
相关论文
共 50 条
  • [41] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
    Mccoy, Rozalina G.
    Herrin, Jeph
    Swarna, Kavya Sindhu
    Deng, Yihong
    Kent, David M.
    Ross, Joseph S.
    Umpierrez, Guillermo E.
    Galindo, Rodolfo J.
    Crown, William H.
    Borah, Bijan J.
    Montori, Victor M.
    Brito, Juan P.
    Neumiller, Joshua J.
    Mickelson, Mindy M.
    Polley, Eric C.
    NATURE CARDIOVASCULAR RESEARCH, 2024, 3 (04): : 431 - 440
  • [42] The pan-PPAR agonist lanifibranor significantly improves cardiovascular risk biomarkers in patients with NASH
    Francque, Sven
    Cooreman, Michael
    Baudin, Martine
    Huot-Marchand, Philippe
    Dzen, Lucile
    Louis, Junien Jean
    Broqua, Pierre
    Abdelmalek, Manal
    JOURNAL OF HEPATOLOGY, 2021, 75 : S268 - S268
  • [43] Clinical Usefulness of the Framingham Cardiovascular Risk Profile Beyond Its Statistical Performance The Tehran Lipid and Glucose Study
    Khalili, Davood
    Hadaegh, Farzad
    Soori, Hamid
    Steyerberg, Ewout W.
    Bozorgmanesh, Mohammadreza
    Azizi, Fereidoun
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 176 (03) : 177 - 186
  • [44] The Beta Cell Independent Glucose Lowering Effects of Exendin-4 Is Attenuated with Aging
    Kang, Zhanfang
    Fan, Rongrong
    He, Lan
    Nie, Yaohui
    Xu, Huiming
    Zhao, Hailu
    Ma, Ronald C. W.
    Chan, Juliana C. N.
    Xu, Gang
    DIABETES, 2010, 59 : A438 - A439
  • [45] SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
    Preda, Alberto
    Montecucco, Fabrizio
    Carbone, Federico
    Camici, Giovanni G.
    Luscher, Thomas F.
    Kraler, Simon
    Liberale, Luca
    CARDIOVASCULAR RESEARCH, 2024, 120 (05) : 443 - 460
  • [46] Metabolic profile associated with glucose and cholesterol lowering effects of berberine in Sprague–Dawley rats
    Zhangjian Jiang
    Feng Liu
    Eng Shi Ong
    Sam Fong Yau Li
    Metabolomics, 2012, 8 : 1052 - 1068
  • [47] Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
    Joshi, Parag H.
    Kalyani, Rita R.
    Blumenthal, Roger S.
    Donner, Thomas W.
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (09): : 32B - 42B
  • [48] Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (11) : 1267 - 1271
  • [49] Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
    Yanai, Hidekatsu
    Adachi, Hiroki
    Hakoshima, Mariko
    Katsuyama, Hisayuki
    BIOLOGY-BASEL, 2023, 12 (05):
  • [50] PPARγ-dependent and PPARγ-independent effects on the development of adipose cells from embryonic stem cells
    Vernochet, C
    Milstone, DS
    Iehlé, C
    Belmonte, N
    Phillips, B
    Wdziekonski, B
    Villageois, P
    Amri, EZ
    O'Donnell, PE
    Mortensen, RM
    Ailhaud, G
    Dani, C
    FEBS LETTERS, 2002, 510 (1-2) : 94 - 98
12345